Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Not applicable

Fluid-responsiveness in Children Ventilated With LOW Tidal Volume - The FLOW Study.

NCT07494643 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2025-11-10
Last updated
2026-04-07

Condition(s) studied

Circulatory Failure (Shock)

Investigational drug(s) / intervention(s)

Echocardiographic

Echocardiographic: Patients included in this study would have received volume expansion anyway, as the prescription of 10ml/kg volume expansion by the physician in charge is the main inclusion criterion. The purpose of this study is to evaluate the diagnostic accuracy of a fluid responsiveness test. To this end, patients will undergo echocardiographic assessments, which are non-invasive, non-radiative, well tolerated and commonly used in this population as a standard of care in our center. No additional blood test or invasive parameters will be collected be collected.

Study summary

In this study of diagnostic accuracy, the investigators aim to validate a fluid-responsiveness test in critically ill children mechanically ventilated with low tidal volume. This test is the famous respiratory variability of peak aortic velocity (ΔVPeak), which is based on cardiopulmonary interactions but is only validated in mechanically ventilated children with a tidal volume of at least 8ml/kg, which is uncommon nowadays. This would help physicians to identify children ventilated with low tidal volume and suffering from acute circulatory failure that could benefit from a volume expansion, thus avoiding a potentially useless or even dangerous fluid expansion that could lead to fluid overload.

To this end, the diagnostic accuracy of ΔVPeak to predict fluid responsiveness (define as a 15% increase in echocardiographically measured SV after volume expansion) will be measured in mechanically ventilated children with low tidal volume and requiring fluid bolus.

Eligibility

Sex
ALL
Min age
0 Days
Max age
15 Years
Healthy volunteers
No
Inclusion Criteria: * Age between 0 days and 15 years old * Patient hospitalized in a pediatric intensive care unit. * Prescription of a 10ml/kg (±20%) fluid expansion by the physician in charge, as a standard care treatment of circulatory failure (precise indication is up to the physician in charge). * Mechanical ventilation * Tidal volume \< 6ml/kg (±15%) * Fluid responsiveness echocardiographic assessment as of routine care Exclusion Criteria: * Prematurity (corrected gestational age bellow 37 weeks) * Arythmia * Hemodynamic instability making dangerous the delay necessary for any measurement. * Prone position * Impairment of echocardiographic acoustic window * Extracorporeal membrane oxygenation * Respiratory rate (measured) \> 60 cycles per minute (including high frequency oscillation) * Significant breathing movements (high work of breathing, clinically assessed) * Restlessness with desynchronization patient/ventilator * Open chest * Cardiogenic pulmonary oedema * Known intracardiac or vascular shunt * Known hemodynamically significant valvopathy * Opposition to participate expressed by the patient or by a parent or legal guardian

Primary outcome measure(s)

  • Area under the ROC curve (AUROC, percent) of ΔVPeak to diagnose fluid responsiveness — Baseline
    The primary outcome measure of a diagnostic accuracy study is the discriminative ability of an index test (expressed as an area under the ROC curve) to diagnose a condition (defined by a positive gold-standard reference test). In this study: * The index test is ΔVPeak at baseline = difference between maximal and minimal peak aortic velocity (m/s) during 5 cardiac cycles, divided by mean peak aortic velocity (m/s). Peak aortic velocity is measured by transthoracic echocardiography with pulsed-Doppler in the left ventricular outflow tract from an apical 5-chambers view. * The condition is "fluid responsiveness" * The gold-standard reference test to diagnose fluid responsiveness is a stroke volume (SV) increase of at least 15% between baseline and after volume expansion: ΔSV-VE \> 15% = ((SV after volume expansion - SV at baseline) / SV at baseline) \> 15%. SV (ml) will be measured by transthoracic echocardiography as the product of left ventricular outflow tract surface (cm², from a par

Trial sites (6)

FacilityCityRegionStatus
CHU d'Amiens Picardie Amiens France Recruiting
CHU de BORDEAUX Bordeaux France Recruiting
CHU de LIMOGES Limoges France Recruiting
Hôpital Necker-Enfants Malades Paris France Recruiting
Hôpital Robert Debré Paris France Recruiting
CHU de Rouen Normandie Rouen France Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07494643 on ClinicalTrials.gov ↗ ← All trials in France